1.93

1.05% 0.02

Pre-market: 1.97 0.04 +2.07%

Caribou Biosciences Inc (CRBU)

Overview News Price History Option Chain Financials Why CRBU Down? Discussions Forecast

Caribou Biosciences Inc stock is traded at $1.93, with a volume of 967.23K. It is up +1.05% in the last 24 hours and down -0.52% over the past month. Caribou Biosciences Inc is a clinical-stage Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) genome-editing biopharmaceutical company dedicated to developing transformative therapies for patients with devastating diseases. The company is focused on advancing two clinical-stage allogeneic CAR-T cell therapy product candidates for the treatment of patients with hematologic malignancies: Vispacabtagene regedleucel and CB-011. It operates in one reportable segment, which is the business of developing allogeneic CAR-T cell therapies. Geographically, it operates in the United States and the rest of the World, of which the United States derives the maximum revenue.

Previous Close:

$1.91

Open:

$1.95

24h Volume:

967.23K

Relative Volume:

0.72

Market Cap:

$189.64M

Revenue:

$11.16M

Net Income/Loss:

$-148.13M

P/E Ratio:

-1.215

EPS:

-1.5885

Net Cash Flow:

$-112.35M

1W Performance:

-7.21%

1M Performance:

-0.52%

6M Performance:

-11.87%

1Y Performance:

+124.76%

1-Day Range:

$1.89

$1.985

1-Week Range:

$1.83

$2.08

52-Week Range:

$0.7301

$3.535

Caribou Biosciences Inc Stock (CRBU) Company Profile

Name

Caribou Biosciences Inc

Sector

Healthcare (1106)

Industry

Biotechnology (615)

Phone

510-982-6030

Address

2929 7TH STREET, SUITE 105, BERKELEY

Employee

Twitter

Next Earnings Date

2026-05-14

Latest SEC Filings

CRBU's Discussions on Twitter

Compare CRBU vs VRTX, REGN, ARGX, ALNY, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
CRBU Caribou Biosciences Inc	1.93	189.64M	11.16M	-148.13M	-112.35M	-1.5885
VRTX Vertex Pharmaceuticals Inc	424.36	107.87B	12.32B	4.34B	3.19B	16.86
REGN Regeneron Pharmaceuticals Inc	702.27	73.63B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	794.70	49.42B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	301.11	40.20B	3.71B	313.75M	465.38M	2.2571
ONC Beone Medicines Ltd Adr	297.49	33.06B	5.36B	287.73M	924.18M	2.5229

Caribou Biosciences Inc Stock (CRBU) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jun-03-24	Downgrade	Evercore ISI	Outperform → In-line
Nov-08-23	Initiated	Cantor Fitzgerald	Neutral
Oct-31-23	Initiated	Evercore ISI	Outperform
Jul-11-23	Initiated	Truist	Buy
Feb-18-22	Initiated	RBC Capital Mkts	Outperform
Dec-01-21	Initiated	Oppenheimer	Outperform
Nov-30-21	Initiated	H.C. Wainwright	Buy
Nov-15-21	Upgrade	Citigroup	Neutral → Buy
Aug-17-21	Initiated	BofA Securities	Buy
Aug-17-21	Initiated	Citigroup	Neutral
Aug-17-21	Initiated	SVB Leerink	Outperform

View All

Caribou Biosciences Inc Stock (CRBU) Latest News

May 05, 2026

Caribou Biosciences to Participate in the BofA Securities 2026 Health Care Conference - Investing News Network

May 05, 2026

Caribou Biosciences to participate in BofA Securities Health Care event in Las Vegas - Traders Union

May 05, 2026

May 04, 2026

Caribou Biosciences (CRBU) price target decreased by 22.79% to 8.92 - MSN

May 04, 2026

MSN Money - MSN

May 04, 2026

May 01, 2026

Caribou Biosciences (CRBU) corrects record‑date shares, June 17 virtual annual meeting - Stock Titan

May 01, 2026

Apr 29, 2026

Caribou Biosciences Stock Soars Pre-market On Positive Early Trial Data For Cancer Treatments - MSN

Apr 29, 2026

Caribou Biosciences (NASDAQ:CRBU) Stock Price Down 2.3%Here's Why - MarketBeat

Apr 29, 2026

Apr 25, 2026

SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Caribou Biosciences - TMX Newsfile

Apr 25, 2026

Apr 24, 2026

Caribou Biosciences (NASDAQ: CRBU) sets 2026 director, auditor and charter votes - Stock Titan

Apr 24, 2026

CRBU Earnings History & Surprises | EPS & Revenue Results | CARIBOU BIOSCIENCES INC (NASDAQ:CRBU) - ChartMill

Apr 24, 2026

Apr 22, 2026

CRBU Caribou Biosciences Inc. posts narrower Q4 2025 loss than consensus forecasts, shares rise 2.33 percent amid upbeat investor sentiment.Product Mix - Xã Thanh Hà

Apr 22, 2026

Where could Caribou Bio (CRBU) stock be by the end of 2026 (+4.67%) 2026-04-22Stock Screening - Xã Vĩnh Công

Apr 22, 2026

Apr 21, 2026

Is Agilon Health (AGL) Outperforming Other Medical Stocks This Year? - qz.com

Apr 21, 2026

Apr 19, 2026

CRBU SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Caribou Biosciences, Inc. Stockholders Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire

Apr 19, 2026

CRBU SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Caribou Biosciences, Inc. Investors Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire

Apr 19, 2026

Apr 17, 2026

CRBU Forecast, Price Target & Analyst Ratings | CARIBOU BIOSCIENCES INC (NASDAQ:CRBU) - ChartMill

Apr 17, 2026

Apr 11, 2026

Investment Recap: Should you avoid Caribou Biosciences Inc stock right now2026 Market WrapUp & AI Based Buy/Sell Signal Reports - baoquankhu1.vn

Apr 11, 2026

Apr 10, 2026

Caribou Biosciences (NASDAQ: CRBU) schedules virtual annual meeting June 17, 2026 - Stock Titan

Apr 10, 2026

Apr 08, 2026

CRBU Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI

Apr 08, 2026

Apr 07, 2026

Caribou Biosciences' (CRBU) Buy Rating Reaffirmed at HC Wainwright - MarketBeat

Apr 07, 2026

H.C. Wainwright Maintains Caribou Biosciences(CRBU.US) With Buy Rating, Maintains Target Price $9 - Moomoo

Apr 07, 2026

Apr 06, 2026

Earnings Miss: How does Caribou Biosciences Inc compare to its peersWeekly Profit Report & Long-Term Capital Growth Strategies - baoquankhu1.vn

Apr 06, 2026

Apr 03, 2026

CRBU SEC FilingsCaribou Biosciences, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan

Apr 03, 2026